BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Trial overview
| Disease | Breast cancer treatment and diagnosis |
| Topic | BR004 |
| Description | Primary Objective To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the progression-free survival (PFS), assessed by investigator using RECIST 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo in patients with newly documented HER2-positive measurable metastatic breast cancer. |
| Physicians | Dr. Mohammad JahanzebMD, FACP, FASCO Medical Oncologist Works at 3 centers.Dr. Edgardo SantosMD Medical Oncologist Works at 3 centers. |